HUNTINGTON STATION, NY--(MARKET WIRE)--Jun 13, 2007 -- Medivisor, Inc. (Other OTC:MVSR.PK - News) today announced the extension of an existing contract with Cura Pharmaceutical Co., Inc. Under the new three-year contract, Medivisor will provide direct to physician marketing for Mucotrol(TM), used to treat various forms of oral ulcerations such as mucositis and stomatitis. This commission-based agreement with Cura allows for Medivisor to have the “exclusive” marketing rights for Mucotrol(TM). Furthermore, Cura and Medivisor are also in discussions for other innovative products which Cura intends to market in the USA territory.
